All In Biotech

Drug Trial Radar · NCT03281369

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 219 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

219

Actual

Start

Oct 13, 2017

Primary completion

Oct 9, 2025

Study completion Oct 9, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Halozyme Therapeutics; BioLineRx, Ltd.
First posted
Sep 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer) and esophageal cancer. Two cohorts of patients with gastric cancer have been enrolled in parallel in this study: the second-line (2L) Gastric Cancer Cohort consists of patients with gastric cancer who have progressed after receiving a platinum-containing or fluoropyrimide-containing chemotherapy regimen in the first-line setting, and the first-line (1L) Gastric Cancer Cohort consists of patients with gastric cancer who have not received prior chemotherapy in this setting. In each cohort, eligible patients will be assigned to one of several treatment arms. Additionally, a cohort of patients with esophageal cancer who have not received prior systemic treatment for their disease will be enrolled in this study. Eligible patients will be randomized to chemotherapy or the combination of chemotherapy with checkpoint inhibitor immunotherapy.

Conditions

  • Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

Interventions

  • 5-Fluorouracil (5-FU)Drug

    5-FU 2400 milligrams per square meter (mg/m\^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.

  • LeucovorinDrug

    Leucovorin: 100 mg/m\^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.

  • OxaliplatinDrug

    Oxaliplatin: 100 mg/m\^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.

  • AtezolizumabDrug

    Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.

  • CobimetinibDrug

    Cobimetinib: 60 mg by mouth once a day on Days 1-21 of every 28-day cycle

  • RamucirumabBiological

    Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.

  • PaclitaxelDrug

    Paclitaxel: 80 mg/m\^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.

  • PEGylated recombinant human hyaluronidase (PEGPH20)Biological

    PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.

  • BL-8040Drug

    BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1-5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).

  • LinagliptinDrug

    Linagliptin: 5 mg orally once a day of every 21-day cycle.

  • AtezolizumabDrug

    Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle

  • CobimetinibDrug

    Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1-21 of every 28-day cycle.

  • CisplatinDrug

    Cisplatin: 80 mg/m\^2 administered by IV infusion on Day 1 of each 21 day cycle. Treatment will be capped after 6 doses.

  • TiragolumabDrug

    Tiragolumab: 600 mg administered by IV infusion on Day 1 of every 21 day cycle.

  • 5-Fluorouracil (5-FU)Drug

    5-FU 800 mg/m\^2 administerd by IV infusion on Days 1-5 of each 21 day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to RECIST v1.1Time frame: From randomization up to approximately 84.2 months

Locations

28 sites in 7 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Cancer Center

    Scottsdale, Arizona

  • Uni of Southern California

    Los Angeles, California

  • UCLA Jonsson Comprehensive Cancer Center

    Santa Monica, California

  • Columbia University Medical Center

    New York, New York

  • Tennessee Oncology - Nashville

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Blacktown Hospital

    Blacktown, New South Wales, Australia

  • Monash Medical Centre-Moorabbin Campus

    Clayton, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Rambam Health Care Campus

    Haifa, Israel

  • Sourasky Medical Centre

    Tel Aviv, Israel

  • Seoul National University Bundang Hospital

    Gyeonggi-do, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Yonsei University College of Medicine (YUCM)-Yonsei Cancer Center

    Seoul, South Korea

  • University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)

    Songpa-gu, South Korea

  • The Catholic University of Korea St. Vincent's Hospital

    Suwon, South Korea

  • Hospital Universitari Vall dHebron

    Barcelona, Spain

  • Universidad de Navarra - Clinica Universitaria de Navarra (CUN)

    Pamplona, Navarre, Spain

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)-CECM

    London, United Kingdom

  • The Royal Marsden

    London, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.